Narcissus and Daffodil

Clinical trials of galanthamine 367
Morierty, P.M. (1995) Transdermal delivery of cholinergic inhibitors: rationale and therapeutic
potential. CNS Drugs, 4 (5), 323–324.
Mucke, H.A.M. (1997) Principles of the therapeutics of galanthamine. Drugs of Today, 33 (4),
251–257.
Office of Population Census and Surveys (1989) Disease Morbidity and Mortality. HMSO,
London.
Office of Technology Assessment, U.S. Congress (1987) Publication No. OTA-BA-323. US
Government Printing Office, Washington D.C.
Perry, E.K. (1987) Cortical neurotransmitter chemistry in Alzheimer’s disease. In: H. Melzer
(ed.), Pharmacology – the Third Generation of Progress. Raven Press, New York.
Perry, E.K., Tomlinson, B.E., Blessed, G., Bergman, K., Gibson, P.H. and Perry, R.H.
(1978) Correlation of cholinergic abnormalities with senile plaques and mental test scores
in senile dementia. British Medical Journal, 2, 1457–1459.
Rainer, M., Mark, T. and Haushofer, A. (1989) Galanthmaine hydrobromide in the treatment
of senile dementia. In: H. Kewitz, T. Thomsen and U. Bickel (eds.), Pharmacological
Interventions of Central Cholinergic Mechanisms in Senile Dementia (Alzheimers Disease),
W. Zuckschwerdt Verlag, Munich, pp. 233–237.
Rainer, M. and Mucke, H. (1996) Long term efficacy and safety of galanthamine in
Alzheimer’s disease: cognitive parameters after two and three years of treatment.
Proceedings of the 8th Congress of the Association of European Psychiatrists, July 1996,
London.
Rainer, M., Mucke, H. and Janoch, P. (1994) Galanthamine treatment in Alzheimer’s
disease: the identification of responders. Abstract No. P174–12. Neuropsychopharmacology,
10 (3S), 215S.
Rosen, W.G., Mohs, R.C. and Davis, K.L. (1984) A new rating scale for Alzheimer’s disease.
American Journal of Psychiatry, 141 (11), 1356–1365.
Rossor, M.N. (1996) Alzheimer’s disease. In: D. J. Weatherall, J.G.C. Leadingham and
D.A. Warrel, (eds.), Oxford Textbook of Medicine, 3rd edn., Oxford University Press, New
York, pp. 3971–3974.
Sunderland, T., Tanot, P.N. and Cohen, R.M. (1987) Anticholinergic sensitivity in patients
with dementia of the Alzheimer type and age-matched controls. Archives of General Psychiatry,
44, 418–426.
Thomsen, T., Bickel, U., Fischer, J.P. and Kewitz, H. (1990) Galanthamine hydrobromide
in a long term treatment of Alzheimer’s disease. Dementia, 1, 46–51.
Thomsen, T. and Kewitz, H. (1989) Galanthamine hydrobromide in the treatment of senile
dementia. In: H. Kewitz, T. Thomsen and U. Bickel (eds.), Pharmacological Interventions of
Central Cholinergic Mechanisms in Senile Dementia (Alzheimers Disease), W. Zuckschwerdt
Verlag, Munich, pp. 238–241.
Unni, L.K. (1998) Beyond tacrine. Recently developed cholinesterase inhibitors for the
treatment of Alzheimer’s disease. CNS Drugs, 10 (6), 447–460.
Wade, J.P.H., Mirsen, T.R., Hachinski, V.C., Fishman, M., Lau, C. and Merskey, H. (1987)
The clinical diagnosis of Alzheimer’s disease. Archives of Neurology, 44, 24–29.
Wagstaff, A.J. and McTavish, D. (1994) Tacrine: a review of its pharmacodynamic and
pharmacokinetic properties and therapeutic efficacy in Alzheimer’s disease. Drugs and
Ageing, 4 (6), 510–540.
Wesnes, K.E., Scott, M., Morrison, S., Greenwood, D., Russell-Duff, K. and Wilcock, G.K.
(1998) The effect of galanthamine on attention in Alzheimer’s disease. Journal of Psychopharmacology,
12 (3, suppl.) 256.
Whitehouse, P.J., Price, D.L., Clark, A.W., Royle, J.T. and DeLong, M.R. (1981) Alzheimer’s
disease: evidence for selective loss of cholinergic neurones in the nucleus basalis.
Annals of Neurology, 10, 122–126.